Treatment with S–1/CPT–11 and mFOLFOX6 for Unresectable Metastatic Colorectal Cancer–Clinical Use and QOL Assessment–

  • YOSHIMATSU Kazuhiko
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • YOKOMIZO Hajime
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • FUJIMOTO Takashi
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • OTANI Taisuke
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • ITAGAKI Hiroko
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • OSAWA Gakuji
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • MATSUMOTO Atsuo
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • WATANABE Kiyo
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • UMEHARA Arihiro
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • SHIOZAWA Shunichi
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • KATSUBE Takao
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • NARITAKA Yoshihiko
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East
  • OGAWA Kenji
    Department of Surgery, Tokyo Women′s Medical University, Medical Center East

Bibliographic Information

Other Title
  • 進行再発大腸癌に対するS-1/CPT-11,mFOLFOX6の治療経験とQOLの評価
  • Treatment with S–1/CPT–11 and mFOLFOX6 for Unresectable Metastatic Colorectal Cancer–Clinical Use and QOL Assessment–

Search this article

Abstract

進行再発大腸癌に対する化学療法として,S-1/CPT-11,mFOLFOX6を一次,二次治療(順不同)として行った治療経験とアンケートに基づくQOL評価を報告する。<BR> 対象は進行再発大腸癌12例である(S-1/CPT-11先行9例,mFOLFOX6先行3例)。先行レジメンの選択はinformed consent時点での患者の選択に従った。両治療法の奏効率,奏効期間,有害事象,生存期間およびQOLを評価した。<BR> 結果は,S-1/CPT-11先行例の奏効期間10.3カ月,二次治療の奏効期間5カ月,mFOLFOX6先行例の奏効期間3.5カ月,二次治療のS-1/CPT-11は2例が治療継続中で,有害事象は,S-1/CPT-11でGrade3の全身倦怠,mFOLFOX6でGrade3の発熱が各1例,12例中8例に末梢神経障害を認めた。QOL評価はS-1/CPT-11が高く,mFOLFOX6は持続点滴で生活の制限との理由から敬遠された。

Journal

References(23)*help

See more

Details

Report a problem

Back to top